Physician profile
Norma Gordon
NPI 1518263342
$17,423.49
in general payments reported to CMS, 2019-2025
30 companies · $3,216 in 2025
The $3,216 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,935 · 2022: $3,185 · 2023: $4,336 · 2024: $3,751 · 2025: $3,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $750 · Education: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,220.45 |
| Consulting Fee | $750.00 |
| Education | $332.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,630.52 | 2021-2025 | |
| Galderma Laboratories, L.P. | $1,997.82 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Novartis Pharmaceuticals Corporation | $1,923.05 | 2021-2025 | |
| Genzyme Corporation | $1,745.12 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,403.76 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $1,092.79 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $749.73 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $733.85 | 2022-2024 | Vtama |
| Leo Pharma INC. | $649.95 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $620.38 | 2021-2025 | |
| Incyte Corporation | $530.43 | 2021-2024 | Opzelura |
| Ucb, INC. | $478.46 | 2021-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $446.23 | 2021 | |
| Sun Pharmaceutical Industries INC. | $418.02 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $414.59 | 2021-2025 | Jublia, Cabtreo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $369.06 | 2021-2025 | Tremfya |
| Verrica Pharmaceuticals INC. | $203.07 | 2023-2024 | Ycanth |
| Amgen INC. | $172.16 | 2021-2025 | Otezla, Otezla |
| Organon LLC | $153.00 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $138.98 | 2023-2025 | |
| Lilly USA, LLC | $131.93 | 2021-2025 | Ebglyss |
| Journey Medical Corporation | $122.68 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.96 | 2022-2023 | Spevigo |
| Almirall LLC | $66.44 | 2021-2024 | Klisyri |
| Botanix Sb INC | $38.32 | 2025 | Sofdra |
| Epi Health, LLC | $35.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.38 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.75 | 2024 | Simlandi |
| Medtronic, INC. | $13.44 | 2023 | Venaseal |
| Strata Skin Sciences, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.